Skip to main content
Watch Insiders
NAMSHealthcare

NewAmsterdam Pharma Company NV (NAMS) Insider Trading

In the last 90 days, 3 NewAmsterdam Pharma Company NV (NAMS) insiders reported 1 open-market purchase totaling $226,500 and 3 sales totaling $4,661,919. The most recent open-market purchase was reported on Sep 14, 2026. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
1
90-day purchase value
$226,500
Corporate buyers
1
Latest transaction
Sep 30, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 30, 2026Johannes Jacob Pieter KasteleinChief Scientific OfficerSale50,246$25.03$1,257,657
Sep 14, 2026Michael H. DavidsonChief Executive OfficerOpen Market Purchase10,000$22.65$226,500
Sep 4, 2026John W SmitherDirectorSale1,600$25.32$40,512
Aug 24, 2026Johannes Jacob Pieter KasteleinChief Scientific OfficerSale125,000$26.91$3,363,750
Jul 20, 2026Louise Frederika KooijChief Accounting OfficerSale105,000$30.34$3,185,658
Jun 22, 2026Louise Frederika KooijChief Accounting OfficerSale40,000$30.20$1,208,160
May 26, 2026Louise Frederika KooijChief Accounting OfficerSale65,000$35.69$2,319,850

Common questions

NAMS insider trading FAQ

Are NAMS insiders buying or selling?
Over the last 90 days, NAMS insiders were net sellers, reporting $226,500 of open-market purchases and $4,661,919 of sales.
When was the last NAMS insider purchase?
The most recent open-market purchase of NewAmsterdam Pharma Company NV stock by an insider was reported on Sep 14, 2026, one of 1 purchase in the last 90 days.
Where does NAMS insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that NewAmsterdam Pharma Company NV officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.